ArticleInternational journal of molecular sciences2020
Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
Open access · goldAbstract read
In one paragraph
Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies.Journal of Crohn's & colitis · 2024Trial
- From Polymorphisms to Phenotypes:Genes · 2025Article
- Mycobacterial Rv1804c binds to the PEST domain of IκBα and activates macrophage-mediated proinflammatory responses.iScience · 2024Article
- Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease Patients.Journal of Crohn's & colitis · 2024Observational
- Prediction of anti-TNF therapy failure in ulcerative colitis patients by ensemble machine learning: A prospective study.Heliyon · 2023Article
- Smad7 as a positive regulator of intestinal inflammatory diseases.Current research in immunology · 2023Review
- Alterations in circadian rhythms aggravate Acetaminophen-induced liver injury in mice by influencing Acetaminophen metabolization and increasing intestinal permeability.Bioengineered · 2022Article
- A Series of Genes for Predicting Responses to Anti-Tumor Necrosis Factor α Therapy in Crohn's Disease.Frontiers in pharmacology · 2022Article
- Mycobacterium tuberculosis Rv0790c inhibits the cellular autophagy at its early stage and facilitates mycobacterial survival.Frontiers in cellular and infection microbiology · 2022Article
- Highlights From the 2021 Advances in Inflammatory Bowel Diseases Conference: Commentary.Gastroenterology & hepatology · 2021Article
- Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease.Pharmaceutics · 2021Review
- Involvement of Smad7 in Inflammatory Diseases of the Gut and Colon Cancer.International journal of molecular sciences · 2021Review
- Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.Pharmaceutics · 2021Article
- Diagnostic and Predictive Value of Immune-Related Genes in Crohn's Disease.Frontiers in immunology · 2021Article
- Effect of Anti-TNF Therapy on Mucosal Apoptosis Genes Expression in Crohn's Disease.Frontiers in immunology · 2021Article
- Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 16 institutions in 1 country.
Sara Salvador-MartínPharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.ORCID 0000-0003-3720-2581
Irene Raposo-GutiérrezPharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.
Víctor Manuel Navas-LópezPediatric Gastroenterology and Nutrition Unit, Hospital Regional Universitario de Málaga, IBIMA Multidisciplinary Group for Pediatric Research, 29010 Málaga, Spain.
Carmen Gallego-FernándezPharmacy Department, Hospital Regional Universitario de Málaga, 29010 Málaga, Spain.
Ana Moreno-ÁlvarezPediatric Gastroenterology Unit, Department of Pediatrics, A Coruña University Hospital, 15006 A Coruña, Spain.
Alfonso Solar-BogaPediatric Gastroenterology Unit, Department of Pediatrics, A Coruña University Hospital, 15006 A Coruña, Spain.
Rosana Muñoz-CodoceoDepartment of Pediatric Gastroenterology, Hospital Infantil Universitario Niño Jesús, 28009 Madrid, Spain.
Lorena MagallaresDepartment of Pediatric Gastroenterology, University Hospital La Paz, 28046 Madrid, Spain.
Eva Martínez-OjinagaDepartment of Pediatric Gastroenterology, University Hospital La Paz, 28046 Madrid, Spain.
María J FobeloPharmacy Service, Hospital Virgen de Valme, 41014 Sevilla, Spain.ORCID 0000-0002-0546-3966
Antonio Millán-JiménezPediatric Gastroenterology Unit, Hospital Virgen de Valme, 41014 Sevilla, Spain.ORCID 0000-0002-6032-7035
Alejandro Rodriguez-MartinezPediatric Gastroenterology, Hepatology and Nutrition Unit, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain.ORCID 0000-0003-2221-6868
Concepción A VayoPharmacy Service, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain.
Cesar SánchezGastroenterology Unit, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.
Mar TolinGastroenterology Unit, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.
Ferrán BossacomaFundació Sant Joan de Déu, Fundació Salut Emporda, 08950 Barcelona, Spain.
Gemma Pujol-MuncunillDepartment of Pediatric Gastroenterology, Hepatology and Nutrition, Hospital Sant Joan de Déu, 08950 Barcelona, Spain.
Rafael González de CaldasPediatric Gastroenterology Unit, Hospital Reina Sofía, 14004 Córdoba, Spain.
Inés LoverdosPediatric Gastroenterology, Hepatology and Nutrition Unit, Hospital de Sabadell, Corporació Sanitària Universitària Parc Taulí, 08208 Barcelona, Spain.
José A Blanca-GarcíaPediatric Gastroenterology Unit, Hospital Puerta del Mar, 11009 Cadiz, Spain.
Oscar SegarraPediatric Gastroenterology Unit, Hospital Universitario Vall d'Hebrón, 08035 Barcelona, Spain.
Francisco J EizaguirrePediatric Gastroenterology Unit, Hospital Universitario Donostia, 20014 San Sebastián, Spain.
Ruth García-RomeroPediatric Gastroenterology Unit, Hospital Infantil Miguel Servet, 50009 Zaragoza, Spain.ORCID 0000-0002-3017-1340
Vicente Merino-BohórquezUGC Pharmacy Department, Hospital Virgen de la Macarena, 41009 Sevilla, Spain.
María Sanjurjo-SáezPharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.
Luis A López-FernándezPharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, 28007 Madrid, Spain.ORCID 0000-0003-3964-5837
Hospital General Universitario Gregorio Marañón · ESHospital Regional Universitario de Málaga · ESHospital Universitario La Paz · ESHospital Universitario Virgen del Rocío · ESUniversidade da Coruña · ESBiogipuzkoa Health Research Institute · ESDeleted InstitutionFundació Salut i Envelliment UAB · ESHospital Infantil Universitario Niño Jesús · ESHospital Sant Joan de Déu Barcelona · ESHospital Universitario de Valme · ESHospital Universitario Miguel Servet · ESHospital Universitario Puerta del Mar · ESHospital Universitario Reina Sofía · ESHospital Universitario Virgen Macarena · ESVall d'Hebron Hospital Universitari · ES
Funding
Consejería de Educación, Juventud y Deporte, Comunidad de Madrid PEJ16/MED/AI-1260Instituto de Investigación Sanitaria Gregorio Marañón PRE-2018-2Instituto de Salud Carlos III PI16/00559Instituto de Salud Carlos III PI19/00792
Abstract
Around a 20-30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of the work was to identify markers that would predict an early response to anti-TNF drugs in pediatric patients with IBD. The study population included 43 patients aged <18 years with IBD who started treatment with infliximab or adalimumab. Patients were classified into primary responders (
Indexed as
AdalimumabAdolescentalpha-DefensinsAnti-Inflammatory AgentsAntirheumatic AgentsChildChild, PreschoolFemaleGene Expression RegulationHumansInfantInflammatory Bowel DiseasesInfliximabMaleReceptors, Tumor Necrosis Factor, Type IIRNA, MessengerAdalimumabalpha-DefensinsAnti-Inflammatory AgentsAntirheumatic AgentsDEFA5 protein, humanInfliximabReceptors, Tumor Necrosis Factor, Type IIRNA, MessengerSmad7 ProteinSMAD7 protein, humanTLR2 protein, humanTNFRSF1B protein, humanToll-Like Receptor 2TREM1 protein, humanTriggering Receptor Expressed on Myeloid Cells-1Tumor Necrosis Factor-alphaadalimumabbiomarkerCrohn’s diseasegene expressioninfliximabulcerative colitis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.